Log In
BCIQ
Print this Print this
 

BHV-4157

  Manage Alerts
Collapse Summary General Information
Company Biohaven Pharmaceutical Holding Co. Ltd.
DescriptionProdrug formulation of riluzole, a glutamate modulating agent
Molecular Target
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase III
Standard IndicationAtaxia
Indication DetailsTreat spinocerebellar ataxia
Regulatory Designation U.S. - Orphan Drug (Treat spinocerebellar ataxia)
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today